REGENERON PHARMACEUTICALS (1REGN.MI) Stock Fundamental Analysis
BIT:1REGN - Euronext Milan - US75886F1075 - Common Stock - Currency: EUR
Overall 1REGN gets a fundamental rating of 7 out of 10. We evaluated 1REGN against 73 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1REGN a very profitable company, without any liquidiy or solvency issues. 1REGN may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make 1REGN suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year 1REGN was profitable.
1REGN had a positive operating cash flow in the past year.
Each year in the past 5 years 1REGN has been profitable.
Each year in the past 5 years 1REGN had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 11.98%, 1REGN belongs to the best of the industry, outperforming 90.41% of the companies in the same industry.
1REGN has a Return On Equity of 15.31%. This is amongst the best in the industry. 1REGN outperforms 84.93% of its industry peers.
With an excellent Return On Invested Capital value of 8.97%, 1REGN belongs to the best of the industry, outperforming 84.93% of the companies in the same industry.
1REGN had an Average Return On Invested Capital over the past 3 years of 11.56%. This is in line with the industry average of 12.94%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.98% | ||
| ROE | 15.31% | ||
| ROIC | 8.97% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.56%
ROIC(5y)16.89%
1.3 Margins
1REGN has a Profit Margin of 31.94%. This is amongst the best in the industry. 1REGN outperforms 91.78% of its industry peers.
1REGN's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 28.85%, 1REGN belongs to the top of the industry, outperforming 87.67% of the companies in the same industry.
1REGN's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 86.69%, 1REGN belongs to the top of the industry, outperforming 82.19% of the companies in the same industry.
In the last couple of years the Gross Margin of 1REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.85% | ||
| PM (TTM) | 31.94% | ||
| GM | 86.69% |
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
1REGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
1REGN has about the same amout of shares outstanding than it did 1 year ago.
1REGN has less shares outstanding than it did 5 years ago.
1REGN has a better debt/assets ratio than last year.
2.2 Solvency
1REGN has an Altman-Z score of 6.60. This indicates that 1REGN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.60, 1REGN belongs to the top of the industry, outperforming 87.67% of the companies in the same industry.
1REGN has a debt to FCF ratio of 0.91. This is a very positive value and a sign of high solvency as it would only need 0.91 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.91, 1REGN belongs to the best of the industry, outperforming 95.89% of the companies in the same industry.
1REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
1REGN has a Debt to Equity ratio of 0.09. This is in the better half of the industry: 1REGN outperforms 64.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.91 | ||
| Altman-Z | 6.6 |
ROIC/WACC1.03
WACC8.7%
2.3 Liquidity
1REGN has a Current Ratio of 4.93. This indicates that 1REGN is financially healthy and has no problem in meeting its short term obligations.
1REGN has a better Current ratio (4.93) than 82.19% of its industry peers.
1REGN has a Quick Ratio of 4.03. This indicates that 1REGN is financially healthy and has no problem in meeting its short term obligations.
1REGN's Quick ratio of 4.03 is fine compared to the rest of the industry. 1REGN outperforms 76.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.03 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.47% over the past year.
Measured over the past years, 1REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
Looking at the last year, 1REGN shows a small growth in Revenue. The Revenue has grown by 7.52% in the last year.
The Revenue has been growing by 12.55% on average over the past years. This is quite good.
EPS 1Y (TTM)2.47%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-13.93%
Revenue 1Y (TTM)7.52%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%-3.69%
3.2 Future
1REGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.68% yearly.
1REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.87% yearly.
EPS Next Y-20.3%
EPS Next 2Y-5.54%
EPS Next 3Y3.24%
EPS Next 5Y9.68%
Revenue Next Year-5.38%
Revenue Next 2Y0.6%
Revenue Next 3Y4%
Revenue Next 5Y6.87%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 11.98, the valuation of 1REGN can be described as reasonable.
Based on the Price/Earnings ratio, 1REGN is valued cheaply inside the industry as 91.78% of the companies are valued more expensively.
1REGN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.32.
Based on the Price/Forward Earnings ratio of 13.04, the valuation of 1REGN can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1REGN indicates a rather cheap valuation: 1REGN is cheaper than 93.15% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, 1REGN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.98 | ||
| Fwd PE | 13.04 |
4.2 Price Multiples
87.67% of the companies in the same industry are more expensive than 1REGN, based on the Enterprise Value to EBITDA ratio.
83.56% of the companies in the same industry are more expensive than 1REGN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.36 | ||
| EV/EBITDA | 10.18 |
4.3 Compensation for Growth
The excellent profitability rating of 1REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.91
EPS Next 2Y-5.54%
EPS Next 3Y3.24%
5. Dividend
5.1 Amount
1REGN has a yearly dividend return of 0.58%, which is pretty low.
1REGN's Dividend Yield is rather good when compared to the industry average which is at 10.33. 1REGN pays more dividend than 91.78% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, 1REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.58% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-5.54%
EPS Next 3Y3.24%
BIT:1REGN (6/16/2025, 7:00:00 PM)
459
+7.8 (+1.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners91.18%
Inst Owner ChangeN/A
Ins Owners1.6%
Ins Owner ChangeN/A
Market Cap49.56B
Analysts80
Price Target737.5 (60.68%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.58% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-8.66%
Max EPS beat(2)4.93%
EPS beat(4)3
Avg EPS beat(4)1.88%
Min EPS beat(4)-8.66%
Max EPS beat(4)6.79%
EPS beat(8)6
Avg EPS beat(8)2.08%
EPS beat(12)10
Avg EPS beat(12)5.54%
EPS beat(16)13
Avg EPS beat(16)9.63%
Revenue beat(2)0
Avg Revenue beat(2)-5.11%
Min Revenue beat(2)-9.31%
Max Revenue beat(2)-0.91%
Revenue beat(4)1
Avg Revenue beat(4)-1.98%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)2.93%
Revenue beat(8)4
Avg Revenue beat(8)-0.63%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)12
Avg Revenue beat(16)4.32%
PT rev (1m)-24.49%
PT rev (3m)-24.49%
EPS NQ rev (1m)-20.01%
EPS NQ rev (3m)-20.01%
EPS NY rev (1m)-16.27%
EPS NY rev (3m)-16.27%
Revenue NQ rev (1m)-8.66%
Revenue NQ rev (3m)-8.66%
Revenue NY rev (1m)-8.57%
Revenue NY rev (3m)-8.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.98 | ||
| Fwd PE | 13.04 | ||
| P/S | 4.07 | ||
| P/FCF | 19.36 | ||
| P/OCF | 14.5 | ||
| P/B | 1.95 | ||
| P/tB | 2.03 | ||
| EV/EBITDA | 10.18 |
EPS(TTM)38.3
EY8.34%
EPS(NY)35.21
Fwd EY7.67%
FCF(TTM)23.71
FCFY5.17%
OCF(TTM)31.65
OCFY6.9%
SpS112.78
BVpS235.29
TBVpS225.95
PEG (NY)N/A
PEG (5Y)0.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.98% | ||
| ROE | 15.31% | ||
| ROCE | 11.96% | ||
| ROIC | 8.97% | ||
| ROICexc | 11.89% | ||
| ROICexgc | 12.46% | ||
| OM | 28.85% | ||
| PM (TTM) | 31.94% | ||
| GM | 86.69% | ||
| FCFM | 21.03% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.56%
ROIC(5y)16.89%
ROICexc(3y)38.5%
ROICexc(5y)36.52%
ROICexgc(3y)45.41%
ROICexgc(5y)40.67%
ROCE(3y)15.42%
ROCE(5y)22.52%
ROICexcg growth 3Y-3.25%
ROICexcg growth 5Y17.1%
ROICexc growth 3Y-7.38%
ROICexc growth 5Y14.08%
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.91 | ||
| Debt/EBITDA | 0.59 | ||
| Cap/Depr | 199.98% | ||
| Cap/Sales | 7.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 86.71% | ||
| Profit Quality | 65.83% | ||
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.03 | ||
| Altman-Z | 6.6 |
F-Score5
WACC8.7%
ROIC/WACC1.03
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.77%
Profit Quality(5y)77.84%
High Growth Momentum
Growth
EPS 1Y (TTM)2.47%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-13.93%
EPS Next Y-20.3%
EPS Next 2Y-5.54%
EPS Next 3Y3.24%
EPS Next 5Y9.68%
Revenue 1Y (TTM)7.52%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%-3.69%
Revenue Next Year-5.38%
Revenue Next 2Y0.6%
Revenue Next 3Y4%
Revenue Next 5Y6.87%
EBIT growth 1Y-0.68%
EBIT growth 3Y-22.17%
EBIT growth 5Y13.8%
EBIT Next Year-16.54%
EBIT Next 3Y6.1%
EBIT Next 5Y8.17%
FCF growth 1Y17.22%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-7.66%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%